Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been
associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in …

Although KRAS-activating mutations represent the most common oncogenic driver in non-
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …

Faithful eucaryotic cell division requires spatio-temporal orchestration of multiple sequential
events. To ensure the dynamic nature of these molecular and morphological transitions, a …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC)
patients, one of the most relevant breakthroughs is represented by targeted therapies …

Colorectal cancer (CRC) is a heterogeneous disease with a myriad of alterations at the
cellular and molecular levels. Kristen rat sarcoma (KRAS) mutations occur in up to 40% of …

Cyclin-dependent kinases (CDKs) play a key regulating role in the cell cycle, which is almost
universally altered in cancer, leading to sustained proliferation. Early pan-CDK inhibitors …

KRAS is the most frequently mutated oncogene identified in human cancers. Despite the
numerous efforts to develop effective specific inhibitors against KRAS, this molecule has …